Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

Sandra De Meyer, Anne Ghys, Inge Dierynck, Maria Beumont, Donghan Luo, Gaston Picchio, Sandra De Meyer, Anne Ghys, Inge Dierynck, Maria Beumont, Donghan Luo, Gaston Picchio

Abstract

Background: Study C210 was a Phase IIa, exploratory trial to assess the activity of telaprevir on hepatitis C virus (HCV) early viral kinetics in treatment-naïve patients infected with genotype 4 (G4) HCV.

Methods: Patients were randomized to receive peginterferon and ribavirin alone, telaprevir monotherapy (T arm), or telaprevir in combination with peginterferon/ribavirin (TPR arm) for 15 days, followed by a 46- or 48-week standard treatment phase. The current analysis aimed to characterize the genotype and phenotype of HCV G4 variants emerging during telaprevir treatment.

Results: Five of the 8 (62.5%) patients in the telaprevir (T) arm had viral breakthrough (vBT) during the investigational treatment phase (between baseline and Day 15), compared to no patients in the TPR arm. HCV G4 viral variants with a T54A/T mutation were detected in two of these patients, as well as two other patients with detectable HCV RNA at the end of telaprevir treatment. Emergence of the T54A/T mutation was associated with a 2- to 4-fold decreased susceptibility to telaprevir. All patients with vBT during the investigational treatment phase or with a T54A/T mutation achieved undetectable HCV RNA 12 or 24 weeks after end of treatment with subsequent peginterferon/ribavirin treatment.

Conclusions: In this analysis in G4 HCV-infected patients, more patients in the telaprevir monotherapy arm experienced vBT with resistant variants compared to none with telaprevir combination therapy. The most commonly selected mutation T54A in telaprevir-treated G4 HCV patients was previously described in the context of G1 infection.

Trial registration: The trial was registered with ClinicalTrials.gov (NCT00580801).

Figures

Figure 1
Figure 1
Scatter plot showing baseline telaprevir susceptibility versus change in HCV RNA from baseline to Day 3 in patients treated with telaprevir monotherapy. HCV RNA, hepatitis C virus ribonucleic acid; BL, baseline; FC, fold change in IC50 value compared to IC50 from wild-type (con 1b); IC50, 50% inhibiting concentration.
Figure 2
Figure 2
Viral load profiles of individual patients in the telaprevir monotherapy arm with vBT, for both the investigational and standard treatment phases. Panels a-e show data from Patient 1-5. HCV RNA, Hepatitis C virus ribonucleic acid; G, genotype; EOT, end of treatment; TVR disc, telaprevir discontinuation; PR disc, Peginterferon/ribavirin discontinuation; FC, fold change in IC50 value compared to IC50 from wild-type (con 1b); Rep, replicon-based phenotypic assay; Enz, biochemical –based phenotypic assay. HCV genotype based on NS5B genotyping.

References

    1. WHO. Global surveillance and control of hepatitis c. report of a who consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat. 1999;6:35–47.
    1. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–973. doi: 10.1002/hep.20819.
    1. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:41–46.
    1. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology. 2008;47:1371–1383. doi: 10.1002/hep.22127.
    1. Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco California. BMC Infect Dis. 2011;11:208. doi: 10.1186/1471-2334-11-208.
    1. Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD. Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol. 2011;49:3040–3043. doi: 10.1128/JCM.00457-11.
    1. INCIVEK® (telaprevir) US FDA Prescribing Information. Available from: . Accessed May 7 2014.
    1. INCIVO® (telaprevir) EU Summary of Product Characteristics. Available from: . Accessed May 7 2014.
    1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. REALIZE study team: telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428. doi: 10.1056/NEJMoa1013086.
    1. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–462. doi: 10.1053/j.gastro.2009.11.055.
    1. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–1777. doi: 10.1053/j.gastro.2007.02.037.
    1. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One. 2012;7:e34372. doi: 10.1371/journal.pone.0034372.
    1. Lin C, Hanzelka B, Muh U, Kovari L, Bartels DJ, Tigges AM, Miller J, Rao BG, Kwong AD. Telaprevir (VX-950) is a potent inhibitor of HCV NS3-4A proteases derived from genotype non-1 HCV infected patients. J Hepatol. 2007;46(Suppl S1):S8.
    1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology. 2011;54:1433–1444. doi: 10.1002/hep.24641.
    1. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F. Observational VHC4 Study Group: epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat. 2007;14:460–467. doi: 10.1111/j.1365-2893.2006.00823.x.
    1. Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis. 2013;208:1000–1007. doi: 10.1093/infdis/jit274.
    1. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46:640–648. doi: 10.1002/hep.21774.
    1. Kieffer T, Bartels D, Sullivan J, Adiwijaya BS, Zhang EZ, Tigges A, Dorrian J, Spanks J, De Meyer W, Picchio G, Adda N, Kwong AD. Clinical virology results from telaprevir Phase 3 study ADVANCE. (61st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 29–November 2, 2010. Abstract LB-11).
    1. De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G. Analysis of genotype 2 and 3 HCV variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat. 2013;20:395–403. doi: 10.1111/jvh.12046.
    1. Zeuzem S, Sulkowski M, Zoulim F, Sherman KE, Alberti A, Wei LJ, van Baelen B, Sullivan J, Kieffer TL, De Meyer S, Picchio G, Tomaka F, Graham CS8, McHutchison JG. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology. 2010;52(Suppl):436A.
    1. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 2006;70:28–38. doi: 10.1016/j.antiviral.2005.12.003.
    1. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother. 2004;48:4784–4792. doi: 10.1128/AAC.48.12.4784-4792.2004.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi